Blue Matter’s Post

Exploring New Drug Targets for Type 2 Diabetes: Progress and Challenges The global rise in type 2 diabetes mellitus (T2DM) has driven the need for more effective and safer drug therapies. Despite the introduction of new drug classes, significant challenges remain in addressing unmet patient needs. Recent concerns, such as the discovery of carcinogenic contaminants like N-nitroso dimethylamine (NDMA) in metformin, highlight the ongoing issues related to drug purity and safety. Advancements in SGLT-2 inhibitors have shown both promise and limitations, similar to previous developments in GLP-1 receptor agonists and DPP-4 inhibitors. The search for new pharmacological molecules with better selectivity and specificity continues to be critical. Researchers are focusing on understanding the mechanistic characteristics and exposure-related risks of these novel compounds to improve treatment outcomes for T2DM patients. Pharmacists play a vital role in this evolving landscape by ensuring medication safety, educating patients on the latest therapies, and staying informed about new drug developments. References: Kanwal, A., Kanwar, N., Bharati, S., Srivastava, P., Singh, S.P., Amar, S. (2022). Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges, and Opportunities. Biomedicines, 10(2), 331. https://lnkd.in/dYsHuyA8

The rising tide of obesity poses a significant challenge to public health, with substantial economic implications. In the United States alone, the cost of obesity to the healthcare system surpasses $170 billion annually, according to the Centers for Disease Control and Prevention. As obesity rates continue to climb, pharmaceutical companies are investing heavily in innovative weight-loss treatments.  Two major players in this arena are Eli Lilly and Novo Nordisk, both of which have witnessed surging demand for their respective weight-loss drugs. This article delves into a detailed comparison of their pioneering solutions and explores which company holds the edge in the race to combat obesity effectively. Read the full article here: https://lnkd.in/e68aigPC

Pharmaceutical Giants Alkem Laboratories Ltd. and Takeda Join Forces to Bring Vonoprazan to India Alkem Laboratories Ltd. Laboratories has entered into a landmark licensing agreement with Takeda to commercialize Vonoprazan, a novel medication for gastrointestinal disorders, in India. This partnership aims to address a crucial gap in the treatment of conditions such as GERD and gastric ulcers, offering a more effective alternative to traditional proton pump inhibitors. The collaboration enhances Alkem Laboratories Ltd.’s market position in the Indian gastrointestinal sector and aligns with Takeda’s strategy to expand its global footprint by bringing innovative treatments to emerging markets. The successful launch of Vonoprazan in India is expected to significantly improve patient outcomes and set a precedent for future advancements in acid-related disorder treatments. For more details please click the link! https://lnkd.in/d6XB873s #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

In this monthly column, Laura Dormer shares Editor picks from the July issue of the Journal of Comparative Effectiveness Research, partner journal of The Evidence Base®. All articles linked to are Open Access and freely available to read. The journal welcomes pre-submission enquiries, so do get in touch if you would be interested in contributing. #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

MSD's $11.5 billion investment in acquiring Acceleron Pharma is poised to generate substantial returns following the FDA's approval of WINREVAIR (sotatercept), a pivotal asset in the acquisition, for treating pulmonary arterial hypertension. The prevalence of pulmonary hypertension at the population level is estimated to range from 1% to 3%. In 2022, the total prevalent cases of PAH in the 7MM were ~88,000 cases, projected to increase by 2034 at a CAGR of 0.4% during the study period (2020─2034). Females are observed to be more affected by PAH than males. As per DelveInsight Business Research LLP’s 2022 estimates, gender-specific diagnosed prevalent cases of pulmonary arterial hypertension in the US numbered approximately 23,000 females and 7,000 males. The pipeline for Pulmonary Arterial Hypertension is robust, with several drugs in advanced stages of development. Examples include Seralutinib (GB002) by Gossamer Bio, Imatinib (TNX-201) by Tenax Therapeutics, Ralinepag by United Therapeutics Corporation, among others. To know more about how Merck’s WINREVAIR Approval can be a game changer in the pulmonary arterial hypertension treatment market, visit: https://lnkd.in/g8fpqV96 #Merck #AcceleronPharma #WINREVAIR #PulmonaryHypertension #PAH #HealthcareInvestment #FDAApproval #MedicalResearch #DrugPipeline #Biopharma

Improvements in formulations may contribute to #competitive advantage. For instance, in neurodegenerative disease treatments updates, Amneal Pharmaceuticals scores the approval for its updated carb/levodopa formulation, Crexont, for use in Parkinsons Disease, which intends to work fast and last. 🧠 "Crexont demonstrated a statistically significant improvement of 0.5 hours of additional “Good On” time per day — defined as minimum Parkinson’s symptoms without troublesome dyskinesia — with an average of thrice-daily dosing, versus five times a day dosing for the IR formulation." #NeurodegenerativeDisease #ParkinsonsDisease #Crexont #Regulatory #Pharma #Healthcare https://lnkd.in/enHD6b2n

#ScientificSaturday 🔬Ezetimibe ― is a cholesterol-lowering medication that works by inhibiting the absorption of cholesterol in the small intestine, targeting the Niemann-Pick C1-like 1 (NPC1L1) protein. This action results in a reduction of "bad" low-density lipoprotein (LDL) cholesterol levels in the bloodstream, making ezetimibe an effective treatment for reducing the risk of heart disease. It can be prescribed alone or in combination with statins, especially for patients who cannot meet cholesterol targets with statins alone or have issues with statin tolerance. ❗This nationwide cohort study investigates the comparative effectiveness of moderate-intensity statin combined with #ezetimibe therapy versus high-intensity statin monotherapy in patients who have undergone percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Utilizing a large, population-based retrospective cohort from 2013 to 2019, the study matched 10,723 pairs of patients on combination therapy and monotherapy based on propensity scores. The findings reveal that the combination of moderate-intensity statin and ezetimibe was associated with a significantly lower risk of myocardial infarction, stroke, and all-cause mortality compared to high-intensity statin monotherapy. Specifically, the combination therapy group showed a 15% reduction in the risk of adverse cardiovascular outcomes. Additionally, the study noted higher medication adherence rates in the combination therapy group. These results suggest that for patients with ACS undergoing PCI, moderate-intensity statin therapy combined with ezetimibe could be a more effective strategy for reducing cardiovascular risks and improving survival than high-intensity statin monotherapy, highlighting the potential benefits of this combination therapy in routine clinical practice. BioPharma Services Inc. has previously completed multiple clinical trials on Ezetimibe. Trust our world-class Pharmacokinetic team with your next #Phase1, BA/BE or Human Abuse Liability (#HAL) drug development project. Read the full blog here: 👇 https://hubs.li/Q02rX-hm0 Discover our Services: 👇 https://hubs.li/Q02rYj4z0 #clinicalresearch #biopharma #drugdevelopment #drugresearch #cro #clinicaltrials

Spinal Muscular Atrophy Treatment Advances with Biogen’s Higher Dose Nusinersen Showing Significant Motor Function Improvements Biogen’s Phase 2/3 DEVOTE study revealed that a higher dose of nusinersen significantly improves motor function in infants with spinal muscular atrophy compared to a matched sham control group. The study demonstrated promising trends in key biomarkers and motor outcomes with a favorable safety profile. Stephanie Melillo Fradette, Head of Neuromuscular Development at Biogen, emphasized the potential of this higher dose regimen to offer more robust treatment options for SMA patients. Biogen plans to seek regulatory approval to enhance SMA treatment, building on the success of SPINRAZA. For more details please click the link! https://lnkd.in/d2cpcqit #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

🚨 Exciting Progress in Obesity Treatments 🚨 💊 The search for effective oral therapies for obesity is advancing, with promising results from two key contenders: VK2735 by Viking Therapeutics TERN-601 by Terns Pharmaceuticals who recently announced efficacy data. 📊 Achieving a ≥5% weight loss is considered a clinically meaningful response. I've put together charts showcasing the data for both of these drugs from their early-stage trials, taken once daily. 🔍 TERN-601's impressive results which it announced this week reflects its potential as a strong contender in the obesity treatment landscape. The high percentage of patients achieving significant weight loss in such a short period is encouraging and suggests that TERN-601 could quickly become a key player if its safety profile holds up in future studies. 🔬 While TERN-601 stands out for its early efficacy, VK2735 benefits from its more advanced stage of development and long-term efficacy and safety data. 🌟 Stay tuned for more updates as developments in this space continue to unfold!

🚀 Major Milestone in Obesity Treatment 🚀 Palatin has dosed the first patient in its Phase 2 clinical study, combining Bremelanotide with Tirzepatide (GLP-1) for obesity treatment. This groundbreaking study could open doors to a future where obesity treatment is more personalized and effective. With enrollment expected to be completed in 3Q 2024 and topline results coming in 1Q 2025, the future looks promising for weight loss solutions. Data shows that 67% of patients on the popular obesity drugs discontinue use in the first year, often resulting in a rebound effect with patients gaining back most of the weight they lost. Our research indicates that combining an MCR4 agonist with a GLP-1 therapeutic may result in synergistic effects on weight loss at lower and better tolerated doses. Learn more about how we’re advancing treatments that harness the power of the melanocortin system to unlock new therapeutic possibilities. https://lnkd.in/gc8uuHfw #Biotech #Pharma #ObesityTreatment #ClinicalTrials #InvestmentOpportunity #HealthcareInnovation